Zepbound

Description

Zepbound, a brand name for tirzepatide, was approved by the FDA for weight loss in November. It is a dual-agonist drug that activates GIP (glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, aiding in glucose management and helping patients feel fuller longer.